S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
"We need batteries. Literally everywhere." (Ad)
This Is Why Daktronics Fell 40% In One Day 
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
The Critical Minerals Race: U.S. v China (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
The Critical Minerals Race: U.S. v China (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
"We need batteries. Literally everywhere." (Ad)
This Is Why Daktronics Fell 40% In One Day 
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
The Critical Minerals Race: U.S. v China (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
The Critical Minerals Race: U.S. v China (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
"We need batteries. Literally everywhere." (Ad)
This Is Why Daktronics Fell 40% In One Day 
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
The Critical Minerals Race: U.S. v China (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
The Critical Minerals Race: U.S. v China (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
"We need batteries. Literally everywhere." (Ad)
This Is Why Daktronics Fell 40% In One Day 
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
The Critical Minerals Race: U.S. v China (Ad)
On the money: Yellen's next milestone is name on US currency
Biden releasing nearly $36B to aid pensions of union workers
The Critical Minerals Race: U.S. v China (Ad)
Is It Time To Throw In The Towel On Gamestop?
Closing prices for crude oil, gold and other commodities
NASDAQ:RDUS

Radius Health - RDUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$10.08
▼
$10.08
50-Day Range
$10.08
▼
$10.10
52-Week Range
$4.97
▼
$23.00
Volume
4,802 shs
Average Volume
1.17 million shs
Market Capitalization
$480.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Radius Health MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
18.2% Downside
$8.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.89 out of 5 stars

Medical Sector

1015th out of 1,022 stocks

Pharmaceutical Preparations Industry

495th out of 499 stocks

See Top Rated MarketRank™ Stocks Here
RDUS stock logo

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Stock News Headlines

November 10, 2022 | bizjournals.com
Biogen announces new CEO
August 15, 2022 | finance.yahoo.com
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
August 11, 2022 | markets.businessinsider.com
FDA Accepts Menarini Group and Radius Health's Filing Under Priority Review For Breast Cancer Candidate
August 11, 2022 | finance.yahoo.com
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
July 28, 2022 | finance.yahoo.com
Mass. M&A activity picks up among life sciences firms
July 15, 2022 | seekingalpha.com
Golden Age Of Merger Arb: Radius
July 11, 2022 | finance.yahoo.com
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
July 8, 2022 | finance.yahoo.com
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
July 7, 2022 | finance.yahoo.com
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
July 7, 2022 | benzinga.com
Radius Health Publishes Investor Presentation Outlining Company's Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
July 7, 2022 | barrons.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, RADA, GRRB, EPZM
July 7, 2022 | finance.yahoo.com
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
July 6, 2022 | benzinga.com
Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm
July 6, 2022 | apnews.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VMW, CMAX, RDUS, FSTX
July 6, 2022 | apnews.com
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
June 28, 2022 | markets.businessinsider.com
Short Volatility Alert: Radius Health, Inc.
June 28, 2022 | benzinga.com
Equity Alert - The M&A Class Action Firm Announces an Investigation of Radius Health, Inc. - RDUS
June 27, 2022 | apnews.com
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAK
June 25, 2022 | benzinga.com
RADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the Firm
June 24, 2022 | seekingalpha.com
Hot Stocks: KMX, BB rise on earnings; WOLF upgrade; RDUS slips after previous day's gains
June 24, 2022 | bizjournals.com
Equity firms to take Radius Health private for $890M
June 24, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Radius Health
June 23, 2022 | apnews.com
RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders
June 23, 2022 | marketwatch.com
Radius Health Shares Leap on Deal to Be Taken Private >RDUS
June 23, 2022 | seekingalpha.com
Radius Health jumps 14% on $890M buyout offer
See More Headlines

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Company Calendar

Last Earnings
11/08/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
CUSIP
N/A
CIK
1428522
Web
www.radiuspharm.com
Phone
(617) 551-4000
Fax
617-551-4701
Employees
293
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.25
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-14.7%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-70,180,000.00
Net Margins
-30.73%
Pretax Margin
-30.73%
Return on Equity
N/A
Return on Assets
-40.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.67
Quick Ratio
1.52

Sales & Book Value

Annual Sales
$229.97 million
Price / Sales
2.09
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.74) per share
Price / Book
-1.76

Miscellaneous

Outstanding Shares
47,620,000
Free Float
46,796,000
Market Cap
$480.01 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Mr. G. Kelly Martin (Age 63)
    CEO, Pres & Director
    Comp: $600.48k
  • Ms. Danielle Holtschlag (Age 44)
    VP of Sales & Head of U.S. Sales Channels
    Comp: $299.3k
  • Ms. Chhaya Shah (Age 58)
    Sr. VP & Chief Bus. Officer
    Comp: $631.62k
  • Dr. Stavros C. Manolagas
    Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr. (Age 90)
    DSc, M.D., Founder & Member of the Scientific Advisory Board
  • Dr. Michael Rosenblatt M.D. (Age 74)
    Founder, Board Observer & Member of Scientific Advisory Board
  • Dr. John A. Katzenellenbogen
    Founder & Member of the Scientific Advisory Board
  • Mr. Mark William Conley CPA (Age 60)
    VP, CFO, Principal Accounting Officer & Treasurer
  • Mr. Peter A. Schwartzman
    Head of Corp. Fin.
  • Ethan Holdaway
    Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RDUS Stock - Frequently Asked Questions

Should I buy or sell Radius Health stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings or view top-rated stocks.

What is Radius Health's stock price forecast for 2023?

4 equities research analysts have issued twelve-month price objectives for Radius Health's shares. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.25 in the next twelve months. This suggests that the stock has a possible downside of 18.2%.
View analysts price targets for RDUS or view top-rated stocks among Wall Street analysts.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to the consensus estimate of $61.40 million. During the same period last year, the company earned ($0.14) EPS.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rock Creek Group LP (0.70%), Pura Vida Investments LLC (0.00%), Citadel Advisors LLC (0.00%), Group One Trading L.P. (0.00%), FNY Investment Advisers LLC (0.00%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $10.08.

How much money does Radius Health make?

Radius Health (NASDAQ:RDUS) has a market capitalization of $480.01 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Radius Health have?

The company employs 293 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 12/9/2022 by MarketBeat.com Staff